Drugs for Hypertension
May 18, 2020 (Issue: 1598)
Drugs available for treatment of chronic hypertension
and their dosages, adverse effects, and costs are
listed in the tables. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
- FM Sacks et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344:3.
- D Mozaffarian et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med 2014; 371:624.
- M Roerecke et al. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health 2017; 2:e108.
- SP Whelton et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136:493.
- JD Inder et al. Isometric exercise training for blood pressure management: a systematic review and meta-analysis to optimize benefit. Hypertens Res 2016; 39:88.
- JE Neter et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42:878.
- PK Whelton et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997; 277:1624.
- PK Whelton et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71:2199.
- American College of Cardiology. ASCVD risk estimator plus. Available at: http://tools.acc.org/ASCVD-Risk-Estimator-Plus. Accessed May 7, 2020.
- JT Wright Jr et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169:832.
- GC Roush et al. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014; 19:5.
- G Hripcsak et al. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020; 180:542.
- Sulfonamide cross-reactivity. Med Lett Drugs Ther 2019; 61:44.
- DA Calhoun et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014; 63:451.
- DA Calhoun and WB White. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2:462.
- Drugs for chronic heart failure. Med Lett Drugs Ther 2019; 61:49.
- Aliskiren (Tekturna) for hypertension. Med Lett Drugs Ther 2007; 49:29.
- K Jamerson et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417.
- WH Frishman and E Saunders. ß-adrenergic blockers. J Clin Hypertens (Greenwich) 2011; 13:649.
- CS Wiysonge et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2017; 1:CD002003.
- GL Bakris et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227.
- Nebivolol (Bystolic) for hypertension. Med Lett Drugs Ther 2008; 50:17.
- J Fongemie and E Felix-Getzik. A review of nebivolol pharmacology and clinical evidence. Drugs 2015; 75:1349.
- ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283:1967.
- MY Yakoob et al. The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. Hypertension 2013; 62:375.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
